NEW YORK, August 15 (Praxis Press). Animal studies and some cohort studies in humans have raised concerns about the carcinogenicity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase ...

The enzyme is known as HMG-CoA reductase, and to doctors, it is not obscure. It is, in fact, the very enzyme that statins block in the process of halting cholesterol production. And so ...

3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, was an attractive target in the search for drugs to reduce plasma cholesterol ...

18 Anti–HMG-CoA reductase autoantibodies may also be present in patients with autoimmune myopathy who have never been prescribed statin therapy. 8,10,17,23 Such patients, who made up one third ...

HMG-CoA reductase inhibitors, commonly referred to as statins, are the cornerstone of pharmacologic reduction of elevated low-density lipoprotein cholesterol. LDL-C is the main contributor to ...

Please provide your email address to receive an email when new articles are posted on . Genetic inhibition of HMG-CoA reductase, a state that mimics long-term statin use, was associated with ...

Statins primarily work by inhibiting the enzyme HMG-CoA reductase, a protein that helps make cholesterol in your body. Zocor ...

The CV benefit of statins can be partly explained by their ability to inhibit of HMG-CoA reductase, which subsequently lowers cholesterol and decreases the formation of mevalonate. However ...

This is certainly the case for the use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors — statins — and the risk of new-onset diabetes. Cardiovascular disease is the ...

Disclosure patterns and decision making preferences in BRCA 1/2 mutation carriers with young adult and minor children ...